Teva's Austedo meets in Phase III tardive dyskinesia study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said Austedo deutetrabenazine ( SD-809) met the primary endpoint in the Phase III ARM-TD trial to treat moderate to severe tardive dyskinesia.

Austedo led to an improvement of 3 points on the Abnormal Involuntary Movement Scale (AIMS) from baseline to end of therapy, the primary endpoint, compared to 1.6 points in the placebo group (p=0.0188). ...